{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T14:27:32Z","timestamp":1770992852192,"version":"3.50.1"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[1983,10,1]],"date-time":"1983-10-01T00:00:00Z","timestamp":433814400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother. Pharmacol."],"published-print":{"date-parts":[[1983,10]]},"DOI":"10.1007\/bf00254263","type":"journal-article","created":{"date-parts":[[2004,9,16]],"date-time":"2004-09-16T09:14:23Z","timestamp":1095326063000},"page":"134-136","source":"Crossref","is-referenced-by-count":19,"title":["Sequential inhibition of polyamine synthesis"],"prefix":"10.1007","volume":"11","author":[{"suffix":"Jr.","given":"Raymond P.","family":"Warrell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig J.","family":"Coonley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph H.","family":"Burchenal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF00254263_CR1","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1042\/bj1920941","volume":"192","author":"L Alhonen-Hongisto","year":"1980","unstructured":"Alhonen-Hongisto L, Seppanen P, Janne J (1980) Intracellular putrescine and spermidine deprivation induces increased uptake of the natural polyamines and methylglyoxal bis(guanylhydrazone). Biochem J 192:941","journal-title":"Biochem J"},{"key":"BF00254263_CR2","unstructured":"Burchenal JH, Warrell R, Hanson K, King C, Smith R (1982) Antitumor effects of inhibitors of the polyamine pathway. Proc 13th Int Cancer Congress, p 103"},{"key":"BF00254263_CR3","first-page":"736","volume":"32","author":"C Dave","year":"1973","unstructured":"Dave C, Caballes L (1973) Studies on the uptake of methylglyoxal bis(guanylhydrazone) (CH3-G) and spermidine in mouse leukemia sensitive and resistant to CH3-G. Fed Proc 32:736","journal-title":"Fed Proc"},{"key":"BF00254263_CR4","first-page":"214","volume":"37","author":"BGM Durie","year":"1977","unstructured":"Durie BGM, Salmon SE, Russell DH (1977) Polyamines as markers of response and disease activity in cancer chemotherapy. Cancer Res 37:214","journal-title":"Cancer Res"},{"key":"BF00254263_CR5","first-page":"183","volume":"23","author":"TC Gau","year":"1982","unstructured":"Gau TC, Natale RB (1982) In vitro activity of methylglyoxal bis(guanylhydrazone) (MGBG) \u00b1 \u03b1-DFMO using the human tumor clongenic assay (HTCA). Proc Am Assoc Cancer Res 23:183","journal-title":"Proc Am Assoc Cancer Res"},{"key":"BF00254263_CR6","first-page":"243","volume-title":"Polyamines in biology and medicine","author":"O Heby","year":"1981","unstructured":"Heby O, Janne J (1981) Polyamine antimetabolites: biochemistry, specificity, and biological effects of inhibitors of polyamine synthesis. In: Morris DR, Marton LJ (eds) Polyamines in biology and medicine. Marcell Dekker, New York, p 243"},{"key":"BF00254263_CR7","first-page":"3248","volume":"42","author":"Y Horn","year":"1982","unstructured":"Horn Y, Beal SL, Walach N, Lubich WP, Spigel L, Marton LJ (1982) Further evidence for the use of polyamines as biochemical markers for malignant tumors. Cancer Res 42:3248","journal-title":"Cancer Res"},{"key":"BF00254263_CR8","first-page":"448","volume":"59","author":"J Janne","year":"1981","unstructured":"Janne J, Alhonen-Hongisto L, Seppanen P, Simes M (1981) Use of polyamine antimetabolites in experimental tumors and in human leukaemia. Med Biol 59:448","journal-title":"Med Biol"},{"key":"BF00254263_CR9","first-page":"163","volume":"1","author":"JG Kuhn","year":"1982","unstructured":"Kuhn JG, Knight WA, McDaniel TM, Coltman CA, Whitecar JP, Fabian C, Costanzi JJ (1982) Methylglyoxal bis-guanylhydrazone (methyl-GAG) in the management of non-Hodgkin's lymphoma (NHL). Proc Am Soc Clin Oncol 1:163","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF00254263_CR10","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1073\/pnas.78.4.2355","volume":"78","author":"GD Luk","year":"1981","unstructured":"Luk GD, Goodwin G, Marton LJ, Baylin SB (1981) Polyamines are necessary for the survival of human small-cell lung carcinoma in culture. Proc Nat Acad Sci (USA) 78:2355","journal-title":"Proc Nat Acad Sci (USA)"},{"key":"BF00254263_CR11","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/0006-291X(78)91630-3","volume":"81","author":"PS Mamont","year":"1978","unstructured":"Mamont PS, Duchesne M-C, Grove J, Bey P (1978) Anti-proliferative properties of DL-alpha-difluoromethylornithine in cultured cells. A consequence of the irreversible inhibition of ornithine decarboxylase. Biochem Biophys Res Commun 81:58","journal-title":"Biochem Biophys Res Commun"},{"key":"BF00254263_CR12","volume-title":"Investigational drug brochure: alpha-Difluoromethylornithine (DFMO)","author":"Merrell-Dow Pharmaceuticals Inc.","year":"1981","unstructured":"Merrell-Dow Pharmaceuticals Inc. (1981) Investigational drug brochure: alpha-Difluoromethylornithine (DFMO). Merrell-Dow Inc., Cincinatti, OH, USA"},{"key":"BF00254263_CR13","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1182\/blood.V57.6.1011.1011","volume":"57","author":"RP Warrell","year":"1981","unstructured":"Warrell RP, Lee BJ, Kempin SJ, Lacher MJ, Straus DJ, Young CW (1981) Effectiveness of methyl-GAG (methylglyoxal bis{guanylhydrazone}) in patients with advanced malignant lymphoma. Blood 57:1011","journal-title":"Blood"},{"key":"BF00254263_CR14","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1200\/JCO.1983.1.1.52","volume":"1","author":"RP Warrell","year":"1983","unstructured":"Warrell RP, Burchenal JH (1983) Methylglyoxal bis(guanylhydrazone) (Methyl-GAG): current status and future prospects. J Clin Oncol 1:52","journal-title":"J Clin Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00254263.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF00254263\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00254263","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00254263.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T22:36:18Z","timestamp":1581978978000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF00254263"}},"subtitle":["A phase I trial of DFMO (\u03b1-difluoromethylornithine) and methyl-GAG [methylglyoxal-bis(guanylhydrazone)]"],"short-title":[],"issued":{"date-parts":[[1983,10]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1983,10]]}},"alternative-id":["BF00254263"],"URL":"https:\/\/doi.org\/10.1007\/bf00254263","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[1983,10]]}}}